Literature DB >> 33442854

Prognostic value and clinical predictors of intramyocardial hemorrhage measured by CMR T2* sequences in STEMI.

Maria Ferré-Vallverdú1,2, Elena Sánchez-Lacuesta3, Diego Plaza-López3, José Luis Díez-Gil3, Pilar Sepúlveda-Sanchis4, Carolina Gil-Cayuela4, Alicia Maceira-Gonzalez5, Vicente Miró-Palau3, Anastasio Montero-Argudo6, Luis Martínez-Dolz3, Begoña Igual-Muñoz5.   

Abstract

Recent studies show that microvascular injury consists of microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH). In patients with reperfused ST-segment elevation myocardial infarction (STEMI) quantitative assessment of IMH with T2* cardiovascular magnetic resonance imaging (CMR) appears to be useful in evaluation of microvascular damage. The current study aimed to investigate feasibility of this approach and to correlate IMH with clinical and CMR parameters. A single center observational cohort study was performed in reperfused STEMI patients with CMR examination 7 days (IQR: 5 to 8 days) after percutaneous coronary intervention. Infarct size (IS) and MVO were evaluated in short-axis late gadolinium enhancement sequences and IMH with whole LV volume T2* mapping sequences. Of the 94 patients, MVO was identified in 52% of patients and the median size of MVO was 3% of LV mass (IQR: 1.5 to 5.4%). IMH was present in 28% of patients and the median size of IMH was 1.1% of LV mass (IQR: 0.5 to 2.9%). IMH extent was independently associated with anterior myocardial infarction (p = 0.022) and thrombectomy (p = 0.049). IMH was correlated with MVO (R = 0.62, p < 0.001), necrosis (R = 0.58, p < 0.001) and LVEF (R = -0.21, p = 0.04). Patients with IMH presented higher incidence of MACE events, independently of LVEF (p = 0.022). T2* mapping is a novel imaging approach that proves useful to asses IMH in the setting of reperfused STEMI. T2* IMH extent was associated with anterior infarction and thrombectomy. T2* IMH was associated with higher incidence of MACE events regardless preserved or reduced LVEF.

Entities:  

Keywords:  Cardiac magnetic resonance; Intramyocardial hemorrhage; Microvascular injury; Percutaneous coronary intervention; ST-segment elevation myocardial infarction

Year:  2021        PMID: 33442854     DOI: 10.1007/s10554-020-02142-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  35 in total

1.  The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: after primary percutaneous coronary intervention.

Authors:  Bilian Zhao; Jian Li; Xinping Luo; Qing Zhou; Hua Chen; Haiming Shi
Journal:  Tex Heart Inst J       Date:  2011

2.  Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention.

Authors:  Ronen Jaffe; Thierry Charron; Geoffrey Puley; Alexander Dick; Bradley H Strauss
Journal:  Circulation       Date:  2008-06-17       Impact factor: 29.690

Review 3.  Intramyocardial haemorrhage after acute myocardial infarction.

Authors:  Ryanne P Betgem; Guus A de Waard; Robin Nijveldt; Aernout M Beek; Javier Escaned; Niels van Royen
Journal:  Nat Rev Cardiol       Date:  2014-11-18       Impact factor: 32.419

4.  Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction.

Authors:  Ingo Eitel; Suzanne de Waha; Jochen Wöhrle; Georg Fuernau; Phillipp Lurz; Matthias Pauschinger; Steffen Desch; Gerhard Schuler; Holger Thiele
Journal:  J Am Coll Cardiol       Date:  2014-09-23       Impact factor: 24.094

5.  Cardiovascular magnetic resonance-derived intramyocardial hemorrhage after STEMI: Influence on long-term prognosis, adverse left ventricular remodeling and relationship with microvascular obstruction.

Authors:  Oliver Husser; Jose V Monmeneu; Juan Sanchis; Julio Nunez; Maria P Lopez-Lereu; Clara Bonanad; Fabian Chaustre; Cristina Gomez; Maria J Bosch; Ruben Hinarejos; Francisco J Chorro; Günter A J Riegger; Angel Llacer; Vicente Bodi
Journal:  Int J Cardiol       Date:  2012-06-09       Impact factor: 4.164

Review 6.  Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach.

Authors:  Ronen Jaffe; Alexander Dick; Bradley H Strauss
Journal:  JACC Cardiovasc Interv       Date:  2010-07       Impact factor: 11.195

Review 7.  Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients.

Authors:  Matthijs van Kranenburg; Michael Magro; Holger Thiele; Suzanne de Waha; Ingo Eitel; Alexandre Cochet; Yves Cottin; Dan Atar; Peter Buser; Edwin Wu; Daniel Lee; Vicente Bodi; Gert Klug; Bernhard Metzler; Ronak Delewi; Peter Bernhardt; Wolfgang Rottbauer; Eric Boersma; Felix Zijlstra; Robert-Jan van Geuns
Journal:  JACC Cardiovasc Imaging       Date:  2014-09

Review 8.  Myocardial reperfusion injury: looking beyond primary PCI.

Authors:  Georg M Fröhlich; Pascal Meier; Steven K White; Derek M Yellon; Derek J Hausenloy
Journal:  Eur Heart J       Date:  2013-03-27       Impact factor: 29.983

9.  Association of Myocardial Injury With Serum Procalcitonin Levels in Patients With ST-Elevation Myocardial Infarction.

Authors:  Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Benjamin Henninger; Agnes Mayr; Christoph Brenner; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler
Journal:  JAMA Netw Open       Date:  2020-06-01

Review 10.  Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective.

Authors:  Murat Sezer; Niels van Royen; Berrin Umman; Zehra Bugra; Heerajnarain Bulluck; Derek J Hausenloy; Sabahattin Umman
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

View more
  1 in total

1.  Development and validation of a predictive model for adverse left ventricular remodeling in NSTEMI patients after primary percutaneous coronary intervention.

Authors:  Lili Wang; Tao Liu; Chaofan Wang; Haochen Xuan; Xianzhi Xu; Jie Yin; Xiaoqun Li; Junhong Chen; Dongye Li; Tongda Xu
Journal:  BMC Cardiovasc Disord       Date:  2022-08-27       Impact factor: 2.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.